Literature DB >> 35373006

Arteriovenous Fistula Nonmaturation: What's the Immune System Got to Do with It?

Crystal A Farrington1, Gary Cutter2, Michael Allon1.   

Abstract

Background: Arteriovenous fistula (AVF) nonmaturation is a persistent problem, particularly among female and Black patients. Increasingly, the immune system has been recognized as an important contributor to vascular disease, but few studies have examined immune factors relative to AVF maturation outcomes. This study evaluated the association of serum panel reactive antibodies (PRA), a measure of immune system reactivity assessed in patients undergoing kidney transplant evaluation, with AVF nonmaturation.
Methods: We identified 132 patients at our institution who underwent surgical AVF placement between 2010-2019 and had PRA testing within 1 year of AVF creation. Multivariable logistic regression was used to determine the association of patient demographic and clinical factors, class I and class II PRA levels, and preoperative arterial and venous diameters with AVF maturation outcomes.
Results: AVF nonmaturation was more likely in females than males (44% versus 20%, P=0.003) and in Black than white patients (40% versus 13%, P=0.001). Class II PRA was higher in females than males (12%±23% versus 4%±13%, P=0.02). In the multivariable model, AVF nonmaturation was associated with class II PRA (adjusted odds ratio [aOR], 1.34 per 10% increase; 95% confidence interval [95% CI], 1.04 to 1.82, P=0.02) and Black race (aOR, 3.34; 95% CI, 1.02 to 10.89, P=0.03), but not with patient sex or preoperative arterial or venous diameters. Conclusions: The association of elevated class II PRA with AVF nonmaturation suggests the immune system may play a role in AVF maturation outcomes, especially among female patients.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  AVF; AVF failure; arteriovenous access; arteriovenous fistula; dialysis; dialysis access; immune system; immunology; nonmaturation; panel reactive antibodies; vascular access

Mesh:

Year:  2021        PMID: 35373006      PMCID: PMC8785854          DOI: 10.34067/KID.0003112021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  44 in total

Review 1.  Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway?

Authors:  Timmy Lee
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

2.  Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients.

Authors:  Christopher D Miller; Michelle L Robbin; Michael Allon
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.

Authors:  Clément Gosset; Denis Viglietti; Marion Rabant; Jérôme Vérine; Olivier Aubert; Denis Glotz; Christophe Legendre; Jean-Luc Taupin; Jean-Paul Duong Van-Huyen; Alexandre Loupy; Carmen Lefaucheur
Journal:  Kidney Int       Date:  2017-05-26       Impact factor: 10.612

4.  Risk Factors for Primary Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Retrospective Survival Analysis in Multiple Medical Centers.

Authors:  Maowan Wen; Zheng Li; Jun Li; Wen Zhou; Yu Liu; Hong Liu; Guochun Chen
Journal:  Blood Purif       Date:  2019-05-08       Impact factor: 2.614

Review 5.  C-reactive Protein.

Authors:  Steven Black; Irving Kushner; David Samols
Journal:  J Biol Chem       Date:  2004-08-26       Impact factor: 5.157

Review 6.  Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis.

Authors:  Timmy Lee; Prabir Roy-Chaudhury
Journal:  Adv Chronic Kidney Dis       Date:  2009-09       Impact factor: 3.620

7.  Arteriovenous fistulae vs. arteriovenous grafts: a retrospective review of 1,700 consecutive vascular access cases.

Authors:  A F Schild; E Perez; E Gillaspie; C Seaver; J Livingstone; A Thibonnier
Journal:  J Vasc Access       Date:  2008 Oct-Dec       Impact factor: 2.283

Review 8.  Transplant glomerulopathy.

Authors:  Edward J Filippone; Peter A McCue; John L Farber
Journal:  Mod Pathol       Date:  2017-10-13       Impact factor: 7.842

Review 9.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

10.  Racial Disparities in the Arteriovenous Fistula Care Continuum in Hemodialysis Patients.

Authors:  Joyce Qian; Timmy Lee; Mae Thamer; Yi Zhang; Deidra C Crews; Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2020-10-20       Impact factor: 8.237

View more
  2 in total

1.  Heterogeneous Population of Immune cells Associated with Early Thrombosis in Arteriovenous Fistula.

Authors:  Gunimat Samra; Vikrant Rai; Devendra K Agrawal
Journal:  J Surg Res (Houst)       Date:  2022-07-07

2.  Systemic Profile of Cytokines in Arteriovenous Fistula Patients and Their Associations with Maturation Failure.

Authors:  Laisel Martinez; Mikael Perla; Marwan Tabbara; Juan C Duque; Miguel G Rojas; Nieves Santos Falcon; Simone Pereira-Simon; Loay H Salman; Roberto I Vazquez-Padron
Journal:  Kidney360       Date:  2022-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.